EverX launches digital therapeutic solution 'Mora' for musculoskeletal disorders

EverX's musculoskeletal disorder digital therapy solution 'MORA' logo

[Asia Economy Reporter Chunhee Lee] EverX announced on the 9th that it will begin supplying its musculoskeletal disorder digital therapeutic solution 'MORA' to major domestic university hospitals and orthopedic clinics.

MORA is a digital therapeutic solution in the field of musculoskeletal disorders, offering over 150 extensive rehabilitation and exercise therapy curricula based on medical evidence, along with monitoring functions. Notably, it applies advanced pose-estimation artificial intelligence (AI) technology specialized for musculoskeletal disorders, enabling highly accurate functional assessments and enhancing treatment adherence by including cognitive behavioral therapy solutions.

Rehabilitation and exercise therapy are the most highly recommended treatments for musculoskeletal disorders. However, in actual clinical settings, patient accessibility is low due to economic and physical limitations, often leading patients to deviate to non-medical rehabilitation and exercise, which poses risks such as uncertain treatment effects, safety issues, and secondary injuries. MORA is a digital-based solution designed to address these unmet needs. It enables safe and effective remote exercise therapy through specialist prescriptions, expected to improve the quality of life for the increasing number of musculoskeletal disorder patients annually and reduce related social costs.

MORA underwent beta testing at Seoul Bumin Hospital and the Incheon Hospital of the Korea Workers' Compensation & Welfare Service, where improvements were made based on real user feedback from patients and medical staff to enhance treatment adherence. Starting with service supply to primary and secondary medical institutions, EverX plans to accumulate diverse real-world data while verifying performance and value, continuously expanding the market.

Professor Jaeyoung Park of Uijeongbu Eulji University Hospital, who participated in the MORA beta test, stated, "Rehabilitation and exercise therapy for post-surgical rehabilitation or musculoskeletal pain improvement are primarily required for patients, but due to medical fees and hospital environmental constraints, the treatment gap in Korea is larger compared to the US and Europe. Due to short outpatient times, it is difficult to sufficiently educate patients on post-surgical rehabilitation, but through MORA exercise therapy prescriptions, patients can easily perform medically verified rehabilitation and exercise therapy at home and experience improvement through the monitoring process."

EverX is currently developing a digital therapeutic (DTx) based on the MORA solution for major musculoskeletal disorders, aiming for approval within the year. The first indication is patellofemoral pain syndrome, with clinical trials being prepared in collaboration with Seoul National University Bundang Hospital. Subsequently, the company plans to gradually expand to major joint-related diseases, targeting approval for up to 30 indications within five years. Upon DTx approval, EverX plans rapid supply and commercialization based on medical staff and patients using the MORA service.

Yoon Chan, CEO of EverX, said, "Within just two weeks of starting the beta test, over 100 patients participated, confirming high satisfaction and potential among medical staff and patients, which raises expectations for rapid service expansion in domestic medical institutions. We have also filed trademark applications in the US and Germany and completed the establishment of a local corporation in the US. We will do our best to establish ourselves as a global leader in digital therapeutic solutions for the musculoskeletal field," he added.

This content was produced with the assistance of AI translation services.